Vir Biotechnology, Inc. splits its revenue into 5 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Grant at $12,000.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
303
|
-0
|
239
|
-0
|
64
|
0
|
1
|
3
|
12
|
| Profit Sharing Amount |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
10
share 84.1%
|
| Grant |
0
-87.8%
share 0.1%
|
0
-96.1%
share -6.4%
|
0
-94.0%
share 0.0%
|
0
-99.0%
share -41.4%
|
0
-71.7%
share 0.5%
|
0
share 127.1%
|
0
share 15.1%
|
1
share 40.8%
|
1
share 8.9%
|
| Profit Sharing Amount Constrained |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0
share 0.0%
|
| Other Revenue |
—
|
—
|
—
|
—
|
0
-100.0%
share 0.0%
|
—
|
2
share 125.7%
|
2
share 61.5%
|
1
share 7.0%
|
| License And Collaboration Revenue |
302
+381.8%
share 99.9%
|
-0
-207.7%
share 106.4%
|
239
+48369.7%
share 100.0%
|
-0
+41.4%
share 141.4%
|
64
share 99.5%
|
-0
share -27.1%
|
-0
share -40.8%
|
-0
share -2.3%
|
—
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VIR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Francisco, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1706431
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.